How is Module 7 weighted in the HSC Biology exam?

NESA does not publish a fixed module weighting, but recent papers allocate roughly 25 to 30 percent of total marks to Module 7. Expect 5 to 7 multiple-choice questions, one or two short-answer questions on the immune response or transmission, and a 7 to 9 mark extended response on a named infectious disease and the public health response.

How many named pathogens should I memorise?

At minimum one named example per pathogen group plus three for bacteria and viruses (because they appear most in exams). Aim for tuberculosis, cholera and tetanus (bacteria); influenza, HIV and SARS-CoV-2 (viruses); BSE (prions); Candida and tinea (fungi); malaria and giardiasis (protozoa); and tapeworm (multicellular parasite). For each, learn the disease, the transmission route, the immune response involved, and the management strategy.

What is the difference between innate and adaptive immunity?

Innate immunity is the body's non-specific, immediate response. It includes physical barriers (skin, mucous membranes), chemical barriers (stomach acid, lysozyme), inflammation, phagocytosis by macrophages and neutrophils, and natural killer cells. Adaptive immunity is the body's specific, slower-developing response. It involves B lymphocytes (which produce antigen-specific antibodies) and T lymphocytes (cytotoxic T cells that kill infected cells; helper T cells that coordinate). Memory cells from the adaptive response provide long-term immunity and are what vaccination targets.

How does vaccination work mechanistically?

Vaccines expose the immune system to weakened, killed or component forms of a pathogen (or, increasingly, to mRNA encoding a pathogen antigen). B lymphocytes recognise the antigen and produce antibodies; some differentiate into long-lived memory B cells. On subsequent exposure to the live pathogen, memory cells trigger a rapid and intense secondary response that clears the pathogen before symptoms develop. Herd immunity emerges when enough of a population is vaccinated to interrupt transmission chains.

What is antibiotic resistance and why does it matter?

Antibiotic resistance is the evolution of bacteria able to survive antibiotic exposure. Random mutations confer resistance in a small fraction of any bacterial population. Antibiotic use selects for resistant variants, which then dominate. Major mechanisms include enzymatic breakdown of the antibiotic (penicillinase), efflux pumps, and target modification. Resistance is accelerated by over-prescription, incomplete courses, and routine agricultural use. Strategies to slow resistance include prescribing only when necessary, antibiotic stewardship programs, new drug development, and reducing agricultural use.

What Australian case studies should I know?

Three are well-supported by NESA past papers. Tuberculosis (Mycobacterium tuberculosis) for the bacterial example and immune response. Influenza for annual vaccination programs and antigenic drift. HPV for Australia's world-leading school-based vaccination program (introduced 2007 for girls, extended to boys 2013) and the consequent decline in cervical cancer rates. Adding SARS-CoV-2 for the COVID-19 response (testing, contact tracing, lockdowns, mRNA vaccines) covers most extended response prompts.

NSWBiology

HSC Biology Module 7 Infectious Disease: deep dive on pathogens, immunity and epidemiology

A deep-dive HSC Biology guide on Module 7 (Infectious Disease). Covers all five pathogen groups with named examples, innate and adaptive immunity step by step, epidemiological measures, Australian public health responses, and the extended-response patterns NESA repeats.

Generated by Claude Opus 4.819 min readNESA Biology Stage 6 Syllabus, Module 7 Infectious DiseaseUpdated 2026-06-20

Reviewed by: AI editorial process; not yet individually human-reviewed

Jump to a section

What Module 7 actually demands
Pathogen groups, with named examples
Transmission and entry
The immune response
Epidemiology
Public health responses
Antibiotic resistance
How Module 7 is examined
Check your knowledge

What Module 7 actually demands

Module 7 (Infectious Disease) is the most marker-heavy module in HSC Biology. Combined with Module 8, it accounts for roughly 60 percent of the exam. The content is dense: five pathogen groups, two arms of the immune system, several epidemiological measures, and a long list of named diseases and public health responses.

NESA frames the module around four inquiry questions, but in practice the exam consistently tests five clusters: pathogen types and transmission, the immune response, epidemiology, vaccination and public health, and antibiotic resistance. The recurring extended-response pattern asks you to choose a named disease, describe the pathogen and how it causes disease, describe the immune response, and evaluate one or more management strategies.

Pathogen groups, with named examples

A pathogen is any biological agent that causes disease. NESA recognises five groups.

Bacteria. Prokaryotic, single-celled organisms with a cell wall (peptidoglycan in most). Reproduce by binary fission. Cause disease through toxins (Clostridium tetani secretes tetanospasmin, causing tetanus) or by colonising and damaging host tissue (Mycobacterium tuberculosis colonises the lungs, causing tuberculosis). Treated with antibiotics targeting bacterial-specific structures (cell wall synthesis, ribosomes, DNA gyrase).

Viruses. Acellular particles consisting of nucleic acid (DNA or RNA) wrapped in a protein capsid, sometimes with a lipid envelope. Cannot replicate independently. Bind host cell receptors, inject genetic material, and hijack host machinery to produce viral progeny. Examples: influenza (RNA virus, mutates rapidly), HIV (retrovirus, integrates into host DNA, attacks helper T cells), SARS-CoV-2 (coronavirus, spike protein binds ACE2 receptor). Treated with specific antivirals; antibiotics do not work.

Prions. Misfolded proteins that induce other proteins to misfold. No nucleic acid. Cause spongiform encephalopathies. Example: bovine spongiform encephalopathy (BSE, mad cow disease), variant Creutzfeldt-Jakob disease in humans. Extremely resistant to denaturation by heat, chemicals, and radiation.

Fungi. Eukaryotic, single-celled (yeasts) or multicellular (moulds). Often opportunistic, causing disease in immunocompromised hosts or at surface sites. Examples: tinea (Trichophyton species, causing athlete's foot and ringworm), Candida albicans (causing thrush, particularly in immunosuppressed patients). Treated with antifungals.

Protozoa and multicellular parasites. Eukaryotic organisms ranging from single-celled (Plasmodium causing malaria; Giardia causing giardiasis) to multicellular (tapeworms, hookworms). Transmission is often vector-borne or via contaminated water. Treated with antiparasitic drugs.

For every group, learn at least one specific named disease, the transmission route, and one management strategy.

Influenza A subtype phylogeny: avian H7N9 and H5N1 lineages branch from the human-circulating H3N2 plus H1N1 clade (dashed accent bracket).

Transmission and entry

Direct transmission. Contact (touch, sexual contact), droplet (sneezing, coughing within 1 to 2 metres), vertical (mother to child during pregnancy or birth).

Indirect transmission. Vector-borne (Anopheles mosquito for malaria, Aedes aegypti for dengue), waterborne (Vibrio cholerae for cholera), foodborne (Salmonella for gastroenteritis), airborne (Mycobacterium tuberculosis on aerosols), fomite (objects contaminated with pathogens).

Portals of entry. Respiratory tract, gastrointestinal tract, urogenital tract, broken skin, bloodstream (needles, transfusions, mosquito bites), conjunctiva.

NESA likes diagrams of transmission cycles. A typical malaria cycle diagram shows the Anopheles mosquito as vector, sporozoites entering human blood during a bite, infecting liver cells, then erythrocytes, gametocytes returning to a feeding mosquito, and the cycle repeating.

Plasmodium lifecycle: a four-stage cycle linking the Anopheles mosquito vector with the human liver and red-blood-cell stages of infection.

The immune response

The immune system has two integrated arms.

Innate (non-specific) immunity. First line of defence, immediate.

Physical barriers: skin, mucous membranes, cilia in respiratory tract.
Chemical barriers: stomach acid (pH ~2), lysozyme in tears and saliva, antimicrobial peptides in sweat.
Inflammation: damaged cells and mast cells release histamine; blood vessels vasodilate (redness, heat) and become more permeable (swelling); neutrophils and macrophages are recruited.
Phagocytosis: macrophages and neutrophils engulf and digest pathogens.
Natural killer cells: destroy virus-infected or cancerous cells.
Complement system: cascade of plasma proteins that lyse pathogens, opsonise them for phagocytosis, and recruit inflammatory cells.

Adaptive (specific) immunity. Develops over days. Provides long-term memory.

B lymphocytes. When a B cell's antigen receptor binds a specific antigen, the cell proliferates and differentiates into plasma cells (producing large quantities of antigen-specific antibodies) and memory B cells. Antibodies neutralise toxins, block pathogen-receptor binding, agglutinate pathogens, and mark them for phagocytosis (opsonisation).
T lymphocytes. Cytotoxic T cells recognise infected cells displaying viral antigens on MHC class I molecules and kill them. Helper T cells recognise antigens on MHC class II molecules of antigen-presenting cells and release cytokines that coordinate the response.
Memory cells. Long-lived populations of antigen-specific B and T cells that mount a faster, larger secondary response on re-exposure. This is the basis of vaccination.

A strong extended response can sketch this two-arm structure from memory and trace which cells respond to which pathogen type.

Epidemiology

Epidemiology is the study of disease distribution and determinants in populations. Core measures:

Incidence: number of new cases per unit time per population.
Prevalence: total cases at a point in time per population.
Mortality rate: deaths per population per unit time.
Case fatality rate: deaths among those infected.
Basic reproductive number ( $R_0$ ): average number of secondary infections from one primary case in a fully susceptible population. $R_0 > 1$ means outbreak grows; $R_0 < 1$ means it dies out.

Australian epidemiological case studies you can use include the long-running decline of tuberculosis since BCG vaccination and improved living standards; the near-elimination of indigenous cervical cancer through the HPV vaccination program; and the SARS-CoV-2 response (testing, contact tracing, border controls, mRNA vaccination).

Model outbreak R₀ time series: R peaks above 3 by day 20, the intervention is introduced at day 25, and R falls below 1 around day 41 so the outbreak begins to shrink.

Public health responses

NESA expects familiarity with the toolkit:

Vaccination programs. Australia's National Immunisation Program funds free vaccines against more than a dozen diseases. The HPV program (introduced 2007 for girls, extended to boys 2013) has dramatically reduced cervical pre-cancer rates.
Antibiotic stewardship. National programs to slow resistance.
Quarantine and isolation. Quarantine restricts movement of exposed but healthy individuals; isolation separates the symptomatic.
Contact tracing. Identifying and notifying people exposed to a confirmed case.
Vector control. Removing breeding sites, insecticides, biological control.
Sanitation and clean water. The single largest historical contributor to falling infectious disease mortality.
Public education. Hand hygiene, safe sex, vaccination uptake.

Strong evaluative answers compare two strategies on at least three criteria: effectiveness, accessibility, ethics or social acceptability, and cost.

Antibiotic resistance

Resistance evolves when bacteria carrying random mutations conferring resistance survive antibiotic exposure and pass the gene on. Major mechanisms: enzymatic inactivation (beta-lactamases destroy penicillin); altered target (modified penicillin-binding proteins in MRSA); efflux pumps (active export of antibiotic); reduced permeability. Resistance genes spread within and between species via horizontal gene transfer (plasmids, transduction, transformation).

Drivers include over-prescription, patient non-adherence (incomplete courses), and routine agricultural use (livestock prophylaxis). Mitigation includes stewardship, surveillance, new drug development, phage therapy research, and reducing agricultural use.

How Module 7 is examined

A typical HSC Biology Module 7 exam profile:

Multiple choice. 5 to 7 questions on pathogen recognition, transmission routes, immune cell function, epidemiological measures.
Short answer (3 to 5 marks). Trace an immune response to a specific pathogen; calculate an incidence or prevalence value; describe a transmission cycle.
Extended response (7 to 9 marks). Choose a named infectious disease, describe the pathogen and its mode of disease causation, describe the immune response, and evaluate one or more management strategies.

Check your knowledge

A mix of definitional, calculation/explanation, and exam-style multi-part questions covering this topic. Aim to answer all under exam conditions, then check against the solutions block.

Define prion and explain why prion diseases are particularly difficult to treat compared with bacterial or viral diseases. (3 marks)
Distinguish between direct contact transmission and vector-borne transmission, providing one Australian-relevant named example of each disease and the species or vector responsible. (4 marks)
Data from the Australian Institute of Health and Welfare for a hypothetical outbreak of meningococcal disease in NSW: in 2024, 80 new cases were notified in a population of 8 million; case fatality rate was 8 percent; 350 cases of disease (including ongoing chronic carriers) were recorded at a single point in time. (a) Calculate the incidence per 100,000 population. (b) Calculate the prevalence per 100,000 population. (c) Calculate the expected number of deaths from the 80 cases. (d) Explain why incidence and prevalence can diverge for diseases with carriers or chronic forms. (6 marks)
(a, 3) Outline three innate immune mechanisms by which the human body responds to a Streptococcus pneumoniae infection of the lung. (b, 4) Describe the role of B and T lymphocytes in the adaptive response to the same infection, including clonal selection and the formation of memory cells. (c, 2) Explain why elderly Australians are at higher risk despite intact adaptive immunity. (9 marks)
The diagram (described) shows a malaria transmission cycle: an infected female Anopheles mosquito bites a human, injecting sporozoites; sporozoites travel to the liver and infect hepatocytes; released merozoites enter erythrocytes, replicate, and lyse the cells (fever spike); some merozoites differentiate to gametocytes; another mosquito ingests gametocytes during a blood meal, fertilisation occurs in the mosquito midgut, and oocysts release new sporozoites to the salivary glands. (a) Identify the human host stage at which symptoms of cyclical fever first appear. (b) State two public-health strategies that target specific stages of this cycle and identify which stage each targets. (c) Discuss one reason why a vaccine for malaria has been historically difficult to develop. (6 marks)
(a) Calculate the basic reproductive number $R_0$ if, in a population of 1000 fully susceptible individuals, one initial case produces an average of 4.5 secondary cases over the infectious period. (b) Calculate the herd-immunity threshold $H = 1 - 1/R_0$ . (c) If 1 million people in a NSW region are susceptible, and 60 percent are vaccinated with a vaccine of 85 percent efficacy, calculate the effective protected fraction and determine whether transmission can be sustained. (6 marks)
Compare three classes of vaccine (live attenuated, inactivated/killed, and mRNA) on (a) mechanism of immune stimulation, (b) safety profile in immunocompromised patients, (c) storage requirements, and (d) one named Australian example of each. (6 marks)
The 2009 H1N1 "swine flu" pandemic and the 2019 to 2023 SARS-CoV-2 pandemic both featured rapid global spread, vaccine development under pressure, and substantial public-health responses in Australia. Write an extended response (approximately 250 to 350 words) that: (a) compares the pathogen biology of H1N1 (an influenza A subtype) and SARS-CoV-2 (a coronavirus), referring to genome structure and antigenic variability; (b) compares the Australian public-health responses (border control, contact tracing, quarantine, vaccination); (c) evaluates which response was more successful and why, with specific epidemiological data where possible (e.g. case-fatality rate, excess deaths, GDP impact). (8 marks)

Solutions

Q1: A prion is a misfolded version of a normal cellular protein (PrPSc, derived from PrPC) that catalyses the misfolding of other PrPC molecules, propagating itself without nucleic acid. Prion diseases (e.g. variant Creutzfeldt-Jakob disease, BSE, kuru) are difficult to treat because: prions contain no DNA or RNA, so antibiotics and antivirals targeting nucleic-acid processes are useless; the immune system does not recognise misfolded host protein as foreign (no antigenic difference at the amino-acid level), so adaptive immunity does not develop; and prions resist denaturation by heat (autoclaving), chemicals (formaldehyde, ethanol), and radiation, making instrument sterilisation and decontamination extremely difficult.
Q2: Direct contact transmission occurs when a pathogen is passed person-to-person via skin contact, sexual contact, or large respiratory droplets within 1 to 2 metres. Example: Neisseria gonorrhoeae causing gonorrhoea, transmitted via direct sexual contact between humans. Vector-borne transmission requires an intermediate organism that transfers the pathogen. Example: Ross River virus, transmitted by Aedes vigilax mosquitoes from infected marsupial reservoirs (e.g. wallabies) to humans, particularly in coastal NSW after wet summers.
Q3: (a) Incidence per 100,000: $(80 / 8\,000\,000) \times 100\,000 = 1.0$ per 100,000. (b) Prevalence per 100,000: $(350 / 8\,000\,000) \times 100\,000 = 4.4$ per 100,000. (c) Expected deaths $= 80 \times 0.08 = 6.4$ , that is approximately 6 deaths. (d) Prevalence (4.4 per 100,000) exceeds incidence (1.0 per 100,000) because some individuals are carriers or chronic cases who persist in the population without being recorded as new infections each year. Prevalence accumulates ongoing cases, while incidence counts only new infections per time period.
Q4: (a) Three innate mechanisms against S. pneumoniae in the lung: (i) the ciliated epithelium of the airways traps and propels mucus-coated bacteria upward toward the throat (mucociliary clearance); (ii) alveolar macrophages phagocytose bacteria; (iii) the complement system, activated by bacterial cell-wall components, opsonises bacteria for phagocytosis and forms membrane attack complexes that lyse them. Inflammation (vasodilation, oedema, neutrophil recruitment) is the visible local response. (b) Adaptive response: dendritic cells in the lung engulf S. pneumoniae and present capsular polysaccharide and protein antigens on MHC class II to helper T cells. Helper T cells release cytokines that activate B cells specific to S. pneumoniae antigens (clonal selection); selected B cells proliferate and differentiate into plasma cells producing anti-S. pneumoniae IgG and IgA. A subset of selected B cells become long-lived memory B cells. Cytotoxic T cells play a limited role because the pathogen is extracellular. (c) Elderly Australians have an "immunosenescent" immune system: thymic involution reduces production of naive T cells, B-cell repertoire diversity declines, and memory cells from prior infections may be less responsive. The result is slower and weaker adaptive responses despite the structural machinery being intact. National pneumococcal vaccination is recommended for Australians over 65.
Q5: (a) Symptoms first appear when merozoites lyse erythrocytes in the bloodstream, releasing waste products and triggering inflammatory cytokine release (TNF-alpha, IL-1). Cyclical fever corresponds to synchronised lysis cycles (every 48 to 72 hours depending on Plasmodium species). (b) Public-health strategies: (i) insecticide-treated bed nets and indoor residual spraying target the adult mosquito vector (interrupts the human-to-mosquito and mosquito-to-human bites); (ii) artemisinin-based combination therapy targets the blood-stage parasite in infected humans (treats existing infections and reduces gametocyte production). Other measures: larval control of breeding sites, prophylactic antimalarials for travellers (target liver and blood stages). (c) Vaccine development has been difficult because the parasite has multiple life-cycle stages, each expressing different antigens, so a vaccine must target several stages; the parasite undergoes antigenic variation within a single infection; and the immune response is short-lived. The RTS,S vaccine (Mosquirix) and R21 vaccine offer only partial protection (about 30 to 75 percent reduction in clinical malaria).
Q6: (a) $R_0 = 4.5$ (given). (b) $H = 1 - 1/R_0 = 1 - 1/4.5 = 0.778 = 77.8$ percent. (c) Effective vaccinated fraction with 85 percent efficacy: $0.60 \times 0.85 = 0.51 = 51$ percent of population effectively protected. Since 51 percent < 77.8 percent herd-immunity threshold, transmission can still be sustained: effective $R = R_0 \times (1 - 0.51) = 4.5 \times 0.49 = 2.2 > 1$ , so an outbreak grows.
Q7: (a) Mechanism. Live attenuated: weakened pathogen replicates briefly in the body, presenting a full range of antigens through both MHC I (cytotoxic T cells) and MHC II (helper T cells, B cells). Inactivated: killed pathogen presents antigens to B cells and helper T cells (MHC II only); cytotoxic T-cell response is weak. mRNA: lipid-nanoparticle-encapsulated mRNA enters host cells, which then express the pathogen antigen (typically a surface protein) intracellularly, eliciting both MHC I and MHC II responses similar to live attenuation. (b) Safety in immunocompromised: live attenuated vaccines are contraindicated (risk of uncontrolled replication); inactivated and mRNA vaccines are generally safe. (c) Storage: live attenuated typically -20 to +5 degrees C; inactivated +2 to +8 degrees C (refrigerator); mRNA requires ultra-cold storage (-70 degrees C for Pfizer, -20 degrees C for Moderna). (d) Australian examples: live attenuated MMR (measles, mumps, rubella) for Australian children; inactivated influenza vaccine (annual Fluvax program); mRNA Pfizer-BioNTech and Moderna COVID-19 vaccines distributed under the COVID-19 Vaccination Program (2021 onwards).
Q8: (a) Pathogen biology. H1N1 influenza A has a segmented single-stranded negative-sense RNA genome (eight segments) packaged in a lipid envelope with surface haemagglutinin (H) and neuraminidase (N) proteins. The segmented genome enables antigenic shift through reassortment when two influenza viruses co-infect a host (often pig or bird), producing novel pandemic strains. SARS-CoV-2 has a single positive-sense RNA genome of approximately 30 kb encoding spike (S), envelope, membrane, and nucleocapsid proteins. Antigenic variation occurs through point mutations (antigenic drift) producing variants of concern (Alpha, Delta, Omicron) and through recombination, but not through reassortment. (b) Australian responses. For H1N1 2009: surveillance via the National Notifiable Diseases Surveillance System, school closures during peak weeks, increased antiviral oseltamivir (Tamiflu) stockpiles, and rapid deployment of a pandemic vaccine in late 2009. Border control was light. For SARS-CoV-2 2020 to 2023: stringent border closures from March 2020 (international and state), 14-day hotel quarantine, mandatory mask wearing, lockdowns in NSW and Victoria, contact tracing via QR-code check-ins, and mRNA vaccine rollout from February 2021. (c) Evaluation. The H1N1 pandemic produced an Australian case-fatality rate of approximately 0.04 percent (191 reported deaths) and limited GDP impact, partly because the strain was less severe than feared. The SARS-CoV-2 response prevented approximately 40,000 deaths in Australia by mid-2022 (compared with per-capita US/UK rates), with cumulative Australian deaths around 25,000 by 2023, a case-fatality rate of roughly 0.4 percent (10x H1N1). Economic costs were substantial (GDP fell 7 percent in Q2 2020 and recovered slowly), and the program required tight social cohesion. The SARS-CoV-2 response was more comprehensive and more successful in averting deaths per capita, but with much greater economic and social disruption. The H1N1 response benefited from a milder pathogen and existing pandemic plans, but the rapid mRNA vaccine development for SARS-CoV-2 marked a generational advance in vaccine technology.